

Anti-CD3 & CD20 Reference Antibody (Epcoritamab)

Catalog # APR11560

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P07766 & P11836
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information


Target/Specificity	CD20,CD3
Expression system	CHO

Protein Information

Images





Anti-CD3 & CD20 Reference Antibody (Epcoritamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-CD3 & CD20 Reference Antibody (Epcoritamab) is more than 99.00%, determined by SEC-HPLC.


Epcoritamab bound to CD3e protein, and then rebounded to secondary antibodies (Anti-human- κ + λ -HRP), and read OD450. As shown in fig, Epcoritamab bound to hu-CD3e-Fc, and the EC50 was 0.024 nM.




Epcoritamab bound to CD20 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD20-VLP, and the EC50 was 0.095 nM.



Epcoritamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to huCD3e-jurkat cells, and the EC50 was 18.920 nM.



Epcoritamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to Raji cells, and the EC50 was 8.393 nM.



Co-incubation of Epcoritamab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Epcoritamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.009 nM.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.